Dr. Burré is awarded R01 from NINDS to investigate the impact of synaptic vesicle-binding of alpha-synuclein on neuron function and neuropathology
Dr. Burrés team will investigate the impact of synaptic vesicle-binding of alpha-synuclein on alpha-synuclein function and neuron survival, using rationally designed variants of alpha-synuclein that stabilize synaptic vesicle-binding. Their study will determine if stabilizing binding of alpha-synuclein on synaptic vesicles reduces alpha-synuclein toxicity and pathology, which will provide important insights into treatment strategies for Parkinson’s disease.